1228 Real-world direct healthcare costs for metastatic colorectal cancer patients treated with cetuximab vs. bevacizumab containing regimen in first-line, or sequentially in first- and second-line, from a US private payer perspective

Private Payer

Comparison of real-world direct healthcare costs for metastatic colorectal cancer patients treated with cetuximab vs. bevacizumab as first-line therapy.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.e17785 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. e17785-e17785

Author(s):

Stephen Johnston ◽

Sarika Ogale ◽

Ellen Riehle ◽

Helen Varker ◽

Paul Juneau ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Real World ◽

Healthcare Costs ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Direct Healthcare Costs ◽

Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line Therapy

Clinical Colorectal Cancer ◽

10.1016/j.clcc.2017.03.014 ◽

2017 ◽

Vol 16 (4) ◽

pp. 386-396.e1 ◽

Cited By ~ 3

Author(s):

Stephen Johnston ◽

Kathleen Wilson ◽

Helen Varker ◽

Elisabetta Malangone-Monaco ◽

Paul Juneau ◽

...

Keyword(s):

Colorectal Cancer ◽

Health Care ◽

Cancer Patients ◽

Real World ◽

Second Line ◽

First Line ◽

Second Line Therapy ◽

Line Therapy ◽

Care Costs

FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial

Annals of Oncology ◽

10.1093/annonc/mdz155.088 ◽

2019 ◽

Vol 30 ◽

pp. iv23-iv24 ◽

Cited By ~ 3

Author(s):

A. Fernández Montes ◽

N. Martinez Lago ◽

J. De la Cámara Gómez ◽

M. Covela Rúa ◽

A. Cousillas Castiñeiras ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Treatment Phase ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

First Line ◽

Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype

International Journal of Oncology ◽

10.3892/ijo.2013.2179 ◽

2013 ◽

Vol 44 (1) ◽

pp. 17-26 ◽

Cited By ~ 6

Author(s):

GEMMA BRUERA ◽

KATIA CANNITA ◽

ALDO VICTOR GIORDANO ◽

ROBERTO VICENTINI ◽

CORRADO FICORELLA ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Line Treatment ◽

Second Line ◽

First Line ◽

Triplet Chemotherapy ◽

Triplet Chemotherapy Plus Bevacizumab

Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data

PharmacoEconomics ◽

10.1007/s40273-020-00951-1 ◽

2020 ◽

Vol 38 (11) ◽

pp. 1263-1275

Author(s):

Koen Degeling ◽

Hui-Li Wong ◽

Hendrik Koffijberg ◽

Azim Jalali ◽

Jeremy Shapiro ◽

...

Keyword(s):

Colorectal Cancer ◽

Overall Survival ◽

Cancer Patients ◽

Real World ◽

Registry Data ◽

First Line ◽

Doublet Chemotherapy

Faculty Opinions recommendation of Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726943980.793538773 ◽

2017 ◽

Author(s):

Noelle LoConte ◽

Kieran Sahasrabudhe

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Iii ◽

First Line ◽

Phase Iii Study ◽

Line Chemotherapy

First‐line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component

Cancer Medicine ◽

10.1002/cam4.3876 ◽

2021 ◽

Author(s):

Yu‐Wen Zhou ◽

Yi‐Xiu Long ◽

Ye Chen ◽

Ji‐Yan Liu ◽

Dan Pu ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Mucinous Adenocarcinoma ◽

First Line ◽

First Line Therapy ◽

Mucinous Component ◽

Line Therapy ◽

CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies

British Journal of Cancer ◽

10.1038/s41416-021-01483-x ◽

2021 ◽

Author(s):

Roberto Moretto ◽

Daniele Rossini ◽

Veronica Conca ◽

Sara Lonardi ◽

Cosimo Rasola ◽

...

Keyword(s):

Colorectal Cancer ◽

Disease Progression ◽

Cancer Patients ◽

Induction Therapy ◽

Pooled Analysis ◽

First Line ◽

The prognostic role of baseline CEA and CA 19-9 values and their time-dependent variations in advanced colorectal cancer patients submitted to first-line therapy

Tumor Biology ◽

10.1007/s13277-014-2693-3 ◽

2014 ◽

Vol 36 (3) ◽

pp. 1519-1527 ◽

Cited By ~ 12

Author(s):

M. Tampellini ◽

A. Ottone ◽

I. Alabiso ◽

C. Baratelli ◽

L. Forti ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Advanced Colorectal Cancer ◽

Time Dependent ◽

Prognostic Role ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Impact of delayed addition of anti-EGFR monoclonal antibodies on the outcome of first-line therapy in metastatic colorectal cancer patients: A retrospective registry-based analysis

Annals of Oncology ◽

10.1093/annonc/mdy281.038 ◽

2018 ◽

Vol 29 ◽

pp. viii165

Author(s):

T. Buchler ◽

O. Fiala ◽

V. Veskrnova ◽

R. Chloupkova ◽

A. Poprach ◽

...

Keyword(s):

Colorectal Cancer ◽

Monoclonal Antibodies ◽

Cancer Patients ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽